The design and fabrication of nanoplatforms with both nuclear medical imaging and therapeutic functions remain challenging in current precision nanomedicine. Herein, we report the design of a novel nanoplatform based on
glucose-modified
dendrimer-entrapped
gold nanoparticles (Au DENPs) labeled with
radionuclide 68Ga and incorporated with
cytosine-
guanine (
CpG) oligonucleotide for positron emission tomography (PET)/computed tomography (CT) dual-mode imaging and
immunotherapy of
tumors. In this study, generation 5
poly(amidoamine) (PAMAM)
dendrimers were first modified to have 8.2
DOTA and 7.3
polyethylene glycol with the other end functionalized with 2-amino-2-deoxy-D-glucose (DG) for each
dendrimer, entrapped with Au NPs, and then radiolabeled with 68Ga through the
DOTA chelation. The synthesized DG-Au DENPs have good cytocompatibility, targeting specificity toward
cancer cells expressing
glucose transporters, and the ability to be labeled by 68Ga with great labeling efficiency (≥85%) and stability (≥95%). After being loaded with CpG, the formed DG-Au DENPs/CpG polyplexes were proven to be used for
tumor dual-mode PET/CT imaging and
immunotherapy by effectively maturing dendritic cells to initiate a T cell-based antitumor immune response in vivo. Compared with the DG-free polyplexes, the developed DG-Au DENPs/CpG polyplexes show a much more sensitive imaging effect and better inhibition effect of
tumors. These findings demonstrate a unique design of 68Ga-labeled DG-Au DENPs, a promising
theranostic nanoplatform that may be extended to tackle different
tumor types.